Maximal Beneficials Foreshows of Adopting De Vega Annuloplasy Technique Addressing Secondary Severe Tricuspid Regurgitation

Abstract

Background: Persistence of significant secondary tricuspid regurgitation (TR) after its repair concomitant with a leftsided valve replacement contributes to increased mortality and morbidity in the immediate and late postoperative periods. Thus, attention is paid to trace risk factors that might affect the success of the repair. However, the knowledge of the exact underlying risk factors and relevant mechanisms contributing to progression of secondary TR is less. Aim of Study:This study aims at identifying the effectiveness of adopting De Vega annuloplasty technique in dealing with cases of secondary severe TR in decreasing or abolishing it (over one year follow-up period) and evaluating the possible risk factors of failure of repair as well. As such, the purpose of addressing agents favoring the best accepted results of the nominated maneuver and planning the optimal surgical method of such secondary TR could be achieved.Patients and Methods: This retrospective observational non-randomized study included 31 patients who had repair of the tricuspid valve (TV) by De Vega annuloplasty technique. They presented with either mitral valve disease and associated secondary severe TR (double valve disease) or combined mitral and aortic valves disease and associated secondary severe TR (triple valve disease). They had been operated upon be either mitral valve replacement (MVR) and De Vega annuloplasty for the TV or combined MVR and aortic valve replacement (AVR) i.e., double valve replacement (DVR) and De Vega annuloplasty for the TV. Postoperative mortality, morbidity outcomes, overall hospital complications, left ventricular ejection fraction (LVEF%), TR degree, functional clinical status, predictorsof failure of TV repair and overall one-year survival were evaluated.Results: Mean age was 37.25±7.31 years. The overall hospital complication rate was 25.80%. No mortality happened during the follow-up period (overall one-year survival rate was 100%). The cumulative duration of the study was 3.167 years.